UNRESECTABLE MELANOMA
Clinical trials for UNRESECTABLE MELANOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE MELANOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an arthritis drug boost melanoma treatment?
Disease control Recruiting nowThis study tests whether adding the arthritis drug sarilumab to a three-drug immunotherapy cocktail can make treatment safer and more effective for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive the combination and be monitore…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated May 17, 2026 04:26 UTC
-
New combo therapy targets tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in 150 people with advanced melanoma or head and neck cancer that hasn't responded to prior immunotherapy. The goal is to see if the combination shrinks tumors and how quickly doctors can use tumor biomarkers to sort patient…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
Second chance: melanoma patients get access to slightly Off-Spec cell therapy
Disease control AVAILABLEThis program offers a special cell therapy called AMTAGVI to people with advanced melanoma that cannot be removed by surgery or has spread. The treatment is made from the patient's own immune cells and is normally only given when it meets strict quality standards. Here, patients …
Matched conditions: UNRESECTABLE MELANOMA
Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 04:11 UTC
-
New hope for tough melanoma: drug combo trial launches
Disease control Recruiting nowThis study tests a new oral drug, LNS8801, alone or with pembrolizumab, in people with advanced melanoma that has stopped responding to standard treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plus pembrolizumab, or stan…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for kidney transplant patients with advanced skin cancer
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Gut health boost may supercharge melanoma therapy
Disease control Recruiting nowThis study looks at whether eating prebiotic foods can improve how well first-line immunotherapy works in people with advanced melanoma that cannot be removed by surgery. About 75 participants will follow a special diet while starting standard immunotherapy. The goal is to see if…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Immune cell army plus drug may slow advanced skin cancer
Disease control Recruiting nowThis study tests whether combining a personalized cell therapy (lifileucel) with an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 670 adults with untreated melanoma will…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE3 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug combo aims to boost immune attack on tough melanoma
Disease control Recruiting nowThis early-stage trial tests a new drug (IOV-3001) combined with an immune cell therapy (lifileucel) in adults with advanced melanoma that has stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can help control the disease. About…
Matched conditions: UNRESECTABLE MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Blood test and scan combo may predict melanoma treatment success
Knowledge-focused Recruiting nowThis study looks at whether combining a special PET/CT scan with a blood test for tumor DNA can help doctors predict which patients with advanced melanoma will respond to immunotherapy. Researchers will compare changes in the scan and blood test results from before treatment to a…
Matched conditions: UNRESECTABLE MELANOMA
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC